# Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions

## TL;DR

A new docetaxel formulation using nanomicelles reduces allergic reactions, potentially improving cancer treatment safety.

## Contribution

A novel mPEG-PLA-Lys(Fmoc) micellar carrier for docetaxel is developed to reduce hypersensitivity.

## Key findings

- The formulation caused no hemolysis, vascular, or muscle irritation in rabbits.
- No allergic response was observed in guinea pigs using the new formulation.

## Abstract

Background/Objectives: Docetaxel is a potent anti-cancer agent capable of treating various types of cancer. However, it often induces a range of adverse reactions when used with its standard solubilizer, Tween-80, necessitating allergy prophylaxis with dexamethasone prior to administration. To mitigate the risk of allergic reactions, with nanomicelles garnering significant interest due to their enhanced solubility and thermodynamic stability. Methods: In this research, a mPEG-PLA-Lys(Fmoc) micellar carrier with m = 45 and n = 10 was engineered to encapsulate docetaxel, and its self-assembly into micelles was investigated. Additionally, allergic reaction studies were conducted on animals. Results: The findings indicated that the formulation did not cause hemolysis, vascular, or muscle irritation in rabbits, nor did it elicit an allergic response in guinea pigs. Conclusions: These results suggest that nanomicelle-encapsulated docetaxel can diminish the allergic reactions associated with docetaxel injections, offering a novel approach to enhance the therapeutic utility of this outstanding anti-cancer drug.